Literature DB >> 3207022

Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability.

A Kohlschütter1, R Laabs, M Albani.   

Abstract

The clinical courses of 17 JNCL patients were analyzed retrospectively with the use of a simple, disease-specific scoring system. The mean observation period was 14 years (range 8-18 years). Scores of 0 (maximal dysfunction) to 3 (normal function) were assigned to each patient's vision, intellect, language, motor function, and epilepsy for each year of observation. The lapse of medians and ranges of all patients' scores were established from age 3 to 20 years. This scoring system allowed quantitative description of an individual course in context of the wide natural variability of the disease. Patients with seizures starting before the age of 10 years tended to have intractable epilepsy, to receive multiple antiepileptic drug therapies, and to have poor courses including problems not related to epilepsy. One patient had a course clearly outside the usual variability of JNCL and is thought to represent a genetic variant.

Entities:  

Mesh:

Year:  1988        PMID: 3207022     DOI: 10.1111/j.1651-2227.1988.tb10770.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  17 in total

Review 1.  Neuronal ceroid lipofuscinoses: a review.

Authors:  N Nardocci; F Cardona
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  Clinical trials in rare disease: challenges and opportunities.

Authors:  Erika F Augustine; Heather R Adams; Jonathan W Mink
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

3.  Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease).

Authors:  Heather R Adams; Christopher A Beck; Erika Levy; Rachel Jordan; Jennifer M Kwon; Frederick J Marshall; Amy Vierhile; Erika F Augustine; Elisabeth A de Blieck; David A Pearce; Jonathan W Mink
Journal:  Dev Med Child Neurol       Date:  2010-02-19       Impact factor: 5.449

4.  Lectin histochemistry in brains with juvenile form of neuronal ceroid-lipofuscinosis (Batten disease).

Authors:  K E Wisniewski; D Maslinska
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

5.  Analysis of potential biomarkers and modifier genes affecting the clinical course of CLN3 disease.

Authors:  Anne-Hélène Lebrun; Parisa Moll-Khosrawi; Sandra Pohl; Georgia Makrypidi; Stephan Storch; Dirk Kilian; Thomas Streichert; Benjamin Otto; Sara E Mole; Kurt Ullrich; Susan Cotman; Alfried Kohlschütter; Thomas Braulke; Angela Schulz
Journal:  Mol Med       Date:  2011-08-18       Impact factor: 6.354

Review 6.  Human forms of neuronal ceroid-lipofuscinosis (Batten disease): consensus on diagnostic criteria, Hamburg 1992.

Authors:  A Kohlschütter; R M Gardiner; H H Goebel
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

7.  Substrate Reduction Therapy in Four Patients with Milder CLN1 Mutations and Juvenile-Onset Batten Disease Using Cysteamine Bitartrate.

Authors:  M Gavin; G Y Wen; J Messing; S Adelman; A Logush; E C Jenkins; W T Brown; M Velinov
Journal:  JIMD Rep       Date:  2013-04-16

8.  Neuronal ceroid-lipofuscinosis: preferential metabolic alterations in thalamus and posterior association cortex demonstrated by PET.

Authors:  A G De Volder; S Cirelli; T de Barsy; J M Brucher; A Bol; C Michel; A M Goffinet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

9.  MRI of neuronal ceroid lipofuscinosis. I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis.

Authors:  T Autti; R Raininko; S L Vanhanen; P Santavuori
Journal:  Neuroradiology       Date:  1996-07       Impact factor: 2.804

10.  Low erythrocyte plasmalogen and plasma docosahexaenoic acid (DHA) in juvenile neuronal ceroid-lipofuscinosis (JNCL).

Authors:  A Kohlschütter; B Schade; B Blömer; C Hübner
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.